Company Profile

Acrigen Biosciences Inc
Profile last edited on: 1/4/2022      CAGE: 8B6M2      UEI: GVHYYXAME436

Business Identifier: High precision gene editing systems
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

202 Stanford Avenue
Kensington, CA 94708
   (619) 847-1193
Location: Single
Congr. District: 08
County: Alameda

Public Profile

Acrigen Biosciences is structured around development of gene editing technologies specifically to improve the efficiency and enhance the safety of CRISPR-Cas based gene editing. The firm's technology is focused on utilizing "anti-CRISPR", or ACR proteins, to function as a deactivation of the Cas proteins to serve as a gene editing "off switch." This technology would help eliminate unwanted side effects and unanticipated editing in a patient by providing and more focused and controlled way to us CRISPER based gene editing.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  David Rabuka -- Co-Founder CEO and President

  Joseph Bondy-Denomy -- Founder and SAB chair

  Trevor Collingwood -- Chief Technology Officer

  Tippi Mackenzie -- Advisor & SAB Member

  Michael Schelle -- VP of Research and Operations

Company News

There are no news available.